MARKER THERAPEUTICS, INC. Proceeds from Convertible Debt
MARKER THERAPEUTICS, INC. (MRKR) reported Proceeds from Convertible Debt of $0 for the 3-month period ending 2015-03-31, per its 10-Q/A filed 2016-04-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2016-04-14
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2014-12-31 was -$74.30K.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2014-03-31 was $418.00K.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2013-12-31 was -$196.26K, a 149.56% decline year-over-year.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for fiscal 2014 was $418.00K, a 42.58% decline from fiscal 2013.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for fiscal 2013 was $728.00K, a 20.93% increase from fiscal 2012.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for fiscal 2012 was $602.00K, a 16.91% decline from fiscal 2011.
- MARKER THERAPEUTICS, INC. proceeds from convertible debt for fiscal 2011 was $724.53K, a 421.54% increase from fiscal 2010.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 9 month as first filed | Proceeds from Convertible Debt 12 month | Proceeds from Convertible Debt 12 month as first filed | Proceeds from Convertible Debt 143 month | Proceeds from Convertible Debt 146 month | Proceeds from Convertible Debt 149 month | Proceeds from Convertible Debt 152 month | Proceeds from Convertible Debt 155 month | Proceeds from Convertible Debt 158 month | Proceeds from Convertible Debt 161 month | Proceeds from Convertible Debt 164 month | Proceeds from Convertible Debt 167 month | Proceeds from Convertible Debt 170 month | Proceeds from Convertible Debt 173 month | Proceeds from Convertible Debt 179 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-03-31 | $0.00 10-Q/A · filed 2016-04-14 | -$74.30K derived: sum of 2 quarters · filed 2016-04-14 | ||||||||||||||||
| 2014-12-31 | -$74.30K derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-14 | $418.00K 10-K · filed 2016-04-14 | $4.12M 10-K · filed 2015-04-15 | |||||||||||||||
| 2014-09-30 | $492.30K 10-Q · filed 2014-11-19 | |||||||||||||||||
| 2014-06-30 | $2.85M 10-Q · filed 2014-08-18 | |||||||||||||||||
| 2014-03-31 | $418.00K 10-Q/A · filed 2016-04-14 | $221.74K derived: sum of 2 quarters · filed 2016-04-14 | $920.00K derived: sum of 3 quarters · filed 2016-04-14 | |||||||||||||||
| 2013-12-31 | -$196.26K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-15 | $502.00K derived: sum of 2 quarters · filed 2015-04-15 | $728.00K 10-K/A · filed 2014-04-17 | $2.85M 10-Q/A · filed 2014-05-21 | ||||||||||||||
| 2013-09-30 | $698.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-19 | $934.26K 10-Q · filed 2014-11-19 | $335.00K 10-Q · filed 2013-11-19 | $2.46M 10-Q · filed 2013-11-19 | ||||||||||||||
| 2013-06-30 | $236.00K 10-Q · filed 2014-08-18 | $2.36M 10-Q · filed 2013-08-19 | ||||||||||||||||
| 2013-03-31 | $2.12M 10-Q/A · filed 2013-08-19 | |||||||||||||||||
| 2012-12-31 | $396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $602.00K derived: sum of 2 quarters · filed 2013-11-19 | $602.00K 10-K/A · filed 2014-04-17 | $2.12M 10-K · filed 2013-05-15 | ||||||||||||||
| 2012-09-30 | $206.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-19 | $206.00K 10-Q · filed 2013-11-19 | $1.73M 10-Q · filed 2012-11-19 | |||||||||||||||
| 2012-06-30 | $0.00 10-Q/A · filed 2012-09-12 | $1.52M 10-Q/A · filed 2012-09-12 | ||||||||||||||||
| 2012-03-31 | $1.52M 10-Q · filed 2012-05-21 | |||||||||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $0.00 derived: sum of 2 quarters · filed 2013-05-15 | $220.00K derived: sum of 3 quarters · filed 2013-05-15 | $724.53K 10-K · filed 2013-05-15 | $1.52M 10-K · filed 2012-04-16 | |||||||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-19 | $220.00K derived: sum of 2 quarters · filed 2012-11-19 | $724.53K 10-Q · filed 2012-11-19 | $151.20K derived: sum of 4 quarters · filed 2012-11-19 | $1.52M 10-Q · filed 2011-11-21 | |||||||||||||
| 2011-06-30 | $220.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-09-12 | $724.53K 10-Q/A · filed 2012-09-12 | $151.20K derived: sum of 3 quarters · filed 2012-09-12 | $151.20K derived: sum of 4 quarters · filed 2012-09-12 | $1.52M 10-Q · filed 2011-08-22 | |||||||||||||
| 2011-03-31 | $504.54K 10-Q · filed 2012-05-21 | -$68.80K derived: sum of 2 quarters · filed 2012-05-21 | -$68.80K derived: sum of 3 quarters · filed 2012-05-21 | |||||||||||||||
| 2010-12-31 | -$573.33K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | -$573.33K derived: sum of 2 quarters · filed 2012-04-16 | $138.92K 10-K · filed 2012-04-16 | |||||||||||||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-21 | $712.25K 10-Q · filed 2011-11-21 | ||||||||||||||||
| 2010-06-30 | $712.25K 10-Q · filed 2011-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |